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Interleukin 17-antagonist secukinumab demonstrated 
high efficacy for treatment of psoriasis in randomized 
controlled trials. However, performance in daily practi-
ce may differ from trials. Drug survival is a comprehen-
sive outcome covering effectiveness and safety, suita-
ble for analyses of daily practice. The aim of this study 
was to evaluate drug survival of secukinumab in a dai-
ly practice psoriasis cohort. Data were collected from 
13 hospitals. Drug survival was analysed using Kap-
lan–Meier survival curves, split for reason of discon-
tinuation. In total, 196 patients were included (83% 
biologic experienced). Overall, 12 and 18 months drug 
survival of secukinumab was 76% and 67%, respec-
tively, and was mostly determined by ineffectiveness. 
There was a trend towards shorter drug survival in 
women and in biologic experienced patients. Thirteen 
percent of patients experienced at least one episode 
of fungal infection. This is one of the first studies of 
drug survival of secukinumab in patients with psoria-
sis treated in daily practice. 
Key words: psoriasis; secukinumab; biologics; drug survival; 
effectiveness. 
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Secukinumab, a monoclonal antibody targeting inter-leukin (IL)17A, has been registered for treatment of 
moderate-to-severe plaque psoriasis since 2015 (1, 2). The 
approved regimen for psoriasis is 300 mg subcutaneous 
every week for 4 weeks and once every 4 weeks thereafter. 
Phase III trials reported high response rates for this regi-
men, with 76–91% of patients reaching Psoriasis Area and 
Severity Index (PASI)75 and 54–73% reaching PASI90 
after 12 weeks of therapy (3–6). Based on the biological 
function of IL17A, fungal infections were anticipated as 
a possible side-effect of secukinumab treatment. In the 
FIXTURE trial, Candida infections occurred in 5% of 
patients treated according to the label regimen, but all 
Candida events resolved spontaneously or with standard 
treatment, and none led to discontinuation of the study 
drug (3). It is important to realize, however, that trial 
results reflect efficacy and safety in a highly controlled 
setting, in a patient population shaped by stringent inclu-
sion and exclusion criteria. Therefore, results from daily 
practice may differ from trial results and are important in 
evaluating an agents’ effectiveness and safety profile (7). 
Data on the performance of secukinumab in daily prac-
tice is scarce. Drug survival, defined as the time a patient 
remains on a specific agent, is a comprehensive outcome 
covering effectiveness, safety and patients’ and doctors’ 
preferences (8). It is a suitable parameter for chronic 
diseases requiring long-term treatment, reflecting thera-
peutic success in a real-life setting (8–10). Subanalyses 
can be performed to gain insight into different reasons 
of drug discontinuation. Moreover, variables associated 
with long or short drug survival may be identified.
Our objective was to evaluate the drug survival of 
secukinumab in a multicentre psoriasis cohort, compri-
sing the first patients treated with secukinumab in daily 
practice. 
Initial Results of Secukinumab Drug Survival in Patients with 
Psoriasis: A Multicentre Daily Practice Cohort Study
Juul M. P. A. VAN DEN REEK1#, Lieke J. VAN VUGT1#, Martijn B. A. VAN DOORN2°, Gayle E. VAN DER KRAAIJ3°, Wim J. A. 
DE KORT4, Georges P. H. LUCKER5, Barbara HORVATH6, M. David NJOO7, H. Jorn BOVENSCHEN8, Paul M. OSSENKOPPELE9, 
Marjolein S. DE BRUIN-WELLER10, Marjan DE GROOT11, Roland MOMMERS1, Ruud L. M. A. PREVOO13, Peter C.M. VAN DE 
KERKHOF1, Phyllis I. SPULS3, Wietske KIEVIT14 and Elke M. G. J. DE JONG1,15 
Departments of Dermatology, 1Radboud University Medical Centre, Nijmegen, 2Erasmus Medical Centre, Rotterdam, 3Amsterdam Medical 
Centre, Amsterdam, 4Amphia Ziekenhuis, Breda, 5Zuyderland Medical Centre Heerlen, Heerlen, 6University Medical Centre Groningen, 
Groningen, 7Ziekenhuisgroep Twente, Hengelo, 8Máxima Medical Centre, Eindhoven, 9Ziekenhuisgroep Twente, Almelo, 10University Medical 
Centre Utrecht, Utrecht, 11Antonius Ziekenhuis, Sneek, 12St Anna Ziekenhuis, Geldrop, 13Zuyderland Medical Centre Sittard-Geleen, Geleen, 
14Radboud University Medical Centre, Radboud Institute for Health Sciences, and 15Radboud University, Nijmegen, The Netherlands
#Shared first authorship. These authors contributed equally to this paper. °Shared second authorship. These authors contributed equally 
to this paper.
SIGNIFICANCE
Secukinumab is the first interleukin-17 inhibitor registe-
red for treatment of plaque psoriasis. This study describes 
drug survival, defined as the time a patient remains on 
a specific agent, for patients with psoriasis treated with 
secukinumab in daily practice. Our cohort comprised 196 
patients: 96 from academic and 100 from non-academic 
hospitals. The majority of patients had been treated with 
other biologics prior to commencing secukinumab therapy 
(biologic experienced). Drug survival of secukinumab was 
76% after 12 and 67% after 18 months, and was mostly 
determined by ineffectiveness. Drug survival rates were 
higher for biologic-naive patients compared to biologic ex-
perienced patients.  
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METHODS
A multicentre daily practice cohort study was performed, focusing 
on drug survival of secukinumab in patients with psoriasis. Data 
from 2 prospective psoriasis registries (BioCAPTURE and the 
local database of the Academic Medical Centre (AMC), Amster-
dam) were combined with retrospective data from other centres 
in the Netherlands. In total, 196 patients from 5 academic and 8 
non-academic centres were included (Table I). Written informed 
consent was obtained for patients included in the BioCAPTURE 
and AMC registry. The medical ethics committee declared that 
written informed consent was not needed for the retrospective, 
anonymized collection of regular care data from other hospitals.
Patients
All patients had a clinical diagnosis of plaque psoriasis and were 
treated with secukinumab in a daily practice setting between May 
2015 and May 2017. Inclusion took place during the entire study 
period, meaning that follow-up durations vary between patients, 
from several months to the entire study period. Patients who had 
previously received secukinumab in a clinical trial were excluded. 
Patients who were treated with secukinumab primarily for psoriatic 
arthritis by the rheumatologist were also excluded. If patients were 
treated with secukinumab multiple times, only the first treatment 
episode was used for the analyses. 
Treatment
Patients were treated according to the psoriasis label with 300 mg 
secukinumab at week 0, 1, 2, 3 and 4 and once every 4 weeks there-
after. Deviations from this schedule were analysed and described. 
Patients using combination treatments with other anti-psoriatic 
agents (systemic or topical) were also included in the analyses. 
In general, physicians follow the Dutch guidelines, in which it is 
advised to monitor patients every 3 months for PASI, Dermatology 
Life Quality Index (DLQI) and laboratory investigations (11). 
Data collection
Anonymized data on patient characteristics, secukinumab start 
and stop dates, reasons for treatment discontinuation, treatment 
regimens, concomitant medication and adverse events were collec-
ted from all participating centres, according to a predesigned data 
collection form. Prospective data were retrieved from the registry 
databases and retrospective data were collected from patient files.
The following adverse events were collected: any adverse events 
classified by the physician as important or severe, any infection 
classified as severe, all fungal infections, and cardiovascular 
events. Incidence rates were calculated as first occurrence of an 
adverse event per patient, divided by the sum of follow-up years 
for this cohort. Normally, only time until the first occurrence of 
an adverse event is taken into account. However, as the exact time 
until occurrence of an adverse event was often not available, total 
follow-up time was used, leading to a slight underestimation of 
incidence rates. As a sensitivity analysis, cumulative number of 
events was divided by the sum of follow-up years for this cohort, 
for events that occurred more than once per patient (e.g. fungal 
infections). 
Statistical analyses
Drug survival was analysed descriptively using Kaplan–Meier 
survival curves. Survival curves were generated for discontinua-
tion; (i) in general; (ii) due to ineffectiveness; and (iii) due to side-
effects. Patients were censored at the moment of their last visit, 
when lost to follow-up, or when secukinumab was discontinued 
for reasons other than inefficacy or side-effects for > 90 days. 
When patients stopped due to a combination of ineffectiveness 
and side-effects, they were counted as having had an event in all 3 
analyses. Subanalyses were performed split for prior biologic use, 
method of data collection and sex. Secukinumab drug survival was 
not directly compared with other biologics, but for contextual pur-
poses, drug survival of other biologics (source: BioCAPTURE) is 
presented as a supplement (Fig. S11). Also a sub-analysis in which 
a 60-day threshold as a maximum gap to determine discontinua-
tion was performed. Log-rank tests were performed if possible 
(no crossing of survival curves). The following baseline variables 
were assessed as possible predictors for drug survival in univariate 
Cox regression analysis: age, sex, age at onset of psoriasis, prior 
biologic use, baseline PASI, body mass index (BMI), weight, 
diagnosis of psoriatic arthritis, baseline C-reactive protein (CRP) 
and treatment setting (academic vs. non-academic). Data were 
analysed using IBM SPSS Statistics, version 22.0.
RESULTS
Patient and treatment characteristics
A total of 196 patients was included: 96 (49%) from 
academic and 100 (51%) from non-academic hospitals. 
The mean and median follow-up duration of patients was 
10.8 and 10.5 months, respectively. The total follow-up 
amounted to 176 patient years. Follow-up was ended 
when patients discontinued secukinumab, when the end 
of the study’s follow-up period (18 months) was reached 
or when patients were lost to follow-up. The mean ± stan-
dard deviation (SD) age at start of secukinumab was 
48.9 ± 13.6 and 119 patients were male (61%). Median 
baseline PASI was 10.9 (range 1.8–45.4). Median BMI 
was 28.7 kg/m2. Diabetes mellitus and hypertension 
affected 39 (20%) and 37 (19%) patients, respectively. 
Forty-six patients (23%) had a diagnosis of psoriatic 
arthritis and 33 patients (17%) were naive to biologics.
Most patients (79%) received secukinumab according 
to the psoriasis label. The most common deviation (12%) 
entailed dose tapering of secukinumab, either by prolong-
ing the interval or by reducing the dose from 300 to 150 
mg per 4 weeks. Other deviations were: use of 150 mg in 
the first weeks or months of treatment because patients 
mistakenly used 1 instead of 2 injections a time (4%), 
use of increased drug dosage by shortening the interval 
to 300 mg per 3 weeks (2%), and other deviations (2%). 
Concomitant systemic antipsoriatic drugs were used in 
Table I. Participating centres
Centre Setting Data collection Patients, n
Radboudumc Academic Prospective 31
Amsterdam MC Academic Prospective 16
Erasmus MC Academic Retrospective 33
UMC Groningen Academic Retrospective 14
UMC Utrecht Academic Retrospective 2
ZGT Hengelo Non-academic Prospective 5
ZGT Almelo Non-academic Prospective 2
St. Anna Geldrop Non-academic Prospective 1
Amphia Breda Non-academic Retrospective 16
MMC Eindhoven Non-academic Retrospective 5
St. Antonius Sneek Non-academic Retrospective 1
Zuyderland Heerlen Non-academic Retrospective 44
Zuyderland Sittard Non-academic Retrospective 26
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11% of patients. Methotrexate was the most common 
concomitant drug, used in 9% of patients. Methotrexate 
was given continuously (6 patients), as bridging therapy 
(4 patients) or started up later during secukinumab 
therapy (10 patients). Detailed patient and treatment cha-
racteristics are shown in Table II. In general, physicians 
follow the Dutch guidelines, in which it is advised to 
monitor patients every 3 months for PASI, DLQI and 
laboratory investigations (11). The exact frequency of 
visits was adequately registered in the leading research 
hospital (Radboudumc). The mean ± SD interval between 
visits was 84 ± 40.4 days. This number is based on the 
last visit before secukinumab start, and all subsequent 
on-drug visits (122 visits in total).
Reasons for discontinuation and adverse events
In total, 49 patients (25%) discontinued secukinumab. 
Ineffectiveness was the most frequent reason for discon-
tinuation of secukinumab (30 patients). Other reasons for 
treatment discontinuation were: side-effects (8 patients), 
a combination of ineffectiveness and side-effects (8 pa-
tients), and other/unknown (3 patients). Amongst patients 
who discontinued due to ineffectiveness (either alone or 
in combination with side-effects), 13 showed primary 
non-response (no response to secukinumab within the 
first 3 months) and 25 experienced loss of effect at a later 
stage. Side-effects leading to treatment discontinuation 
were heterogeneous, but fungal infections were the most 
frequently reported reason (Table III).
Adverse events that developed during treatment are 
reported in Table III. Twenty-five of 196 patients (13%) 
Table II. Patient and treatment characteristics of patients with 
secukinumab (n = 196)
Characteristics
Sex (male), n (%)
Age at start of secukinumab, years, mean ± SD
Age at onset of psoriasis, years, median [range]
Disease duration years, median [range]
119 (60.7)
48.9 ± 13.6a
23.4 [0;65.0]a
21.4 [0.3;61.1]a 
Psoriatic arthritis (yes), n (%) 46 (23.5)a
Weight, kg, median [range]
BMI, kg/m2, median [range]
90.0 [41.0;160.0]a
28.7 [17.8;48.3]a
Baseline PASI, median [range] 10.9 [1.8;45.4]a
Comorbidities, n (%)
  Diabetes mellitus (type 1/2)
  Hypertension
  Cardiovascular events (history of)
  Liver disease (steatosis/fibrosis/cirrhosis)
  Malignancy (solid tumours; history of)
39 (19.9)
37 (18.9)
21 (10.7)
16 (8.2)
5 (2.6)
Prior conventional systemics, n, median [range]
Biologics before secukinumab, n, median [range]
  0 prior biologics, n (%)
  1 prior biologic, n (%)
  2 prior biologics, n (%)
  3 prior biologics, n (%)
  4 prior biologics, n (%)
  5 prior biologics, n (%)
Prior biologic use (yes), n (%)
  Prior tumour necrosis factor inhibitor use (yes), n (%)
  Prior ustekinumab use (yes), n (%)
2 [0;4]
2 [0; 5]
33 (16.8)
38 (19.4)
47 (24.0)
42 (21.4)
27 (13.8)
9 (4.6)
163 (83.2)
154 (78.6)
106 (54.1)
Secukinumab treatment according to psoriasis label (yes), 
n (%)
155 (79.1)
Concomitant drug use, n (%)
  Methotrexate
  Acitretin
  Fumaric acid esters
  Leflunomide
  Sulfasalazine
  Prednisone (including methylprednisolone injections)
  Intensive topical therapy (in-hospital treatment)
18 (9.2)
2 (1.0)
2 (1.0)
2 (1.0)
2 (1.0)
8 (4.1)
5 (2.6)
Status at end of study (18 months), n (%)
  On therapy
  Stopped due to ineffectiveness
  Stopped due to side-effects
  Stopped due to ineffectiveness and side-effects
  Stopped for other/unknown reasons
  Lost to follow-up
147 (75.0)
30 (15.3)
8 (4.1)
8 (4.1)
3 (1.5)
1 (0.5)
aMissings, n (%): age at start secukinumab, 0 (0); age at onset, 46 (23.5); disease 
duration, 46 (23.5); psoriatic arthritis, 20 (10.2); weight, 76 (38.3); body mass 
index (BMI), 98 (50.0); baseline Psoriasis Area and Severity Index (PASI), 85 
(43.4). SD: standard deviation.
Table III. Adverse events in psoriasis patients with secukinumab
n IR* (95% CI)
Fungal infectionsa (n patients)
Fungal infectionsa (n reported events)
  Oropharyngeal fungal infection (n patients)
  Oropharyngeal fungal infection (n reported events)
  Vaginal fungal infection (n patients)
  Vaginal fungal infection (n reported events)
  Fungal infection of the nails (n patients)
  Fungal infection of the nails (n reported events)
25
38
13
21**
  3
  3
  2
  2
14.2 [9.4–20.6]
21.6 [15.5–29.3]
  7.4 [4.1–12.3]
11.9 [7.6–17.9]
  1.7 [0.4–4.6]
  1.7 [0.4–4.6]
  1.1 [0.2–3.7]
  1.1 [0.2–3.7]
  Fungal infection, other localization (n patients) 
  Fungal infection, other localization (n events) 
Severe infections
  Osteomyelitis of left hallux (diabetic patient) 
  Nausea and vomiting (dehydration, renal failure) 
  Septicaemia
Other reported infections
  Erysipelas (or: cellulitis)
  Furunculosis/folliculitis
  Herpes infection (oesophagus or skin)
  Gastro-intestinal Shigella infection 
  Gastro-intestinal Clostridium difficile infection
  Gastro-enteritis (e causa ignota)
  Infection hands/fingers
  Pterygium
  Pneumonia
  Urinary tract infections
  Eye infection
  Ear infection
  Faryngitis
  Impetigo
Auto-immune diseases
  Worsening of pre-existing sarcoidosis 
  Antiphospholipid syndrome 
  9
12
  3
  1
  1
  1
21
  2
  1
  2
  1
  1
  2
  2
  1
  1
  4
  1
  1
  1
  1
  2
  1
  1
  5.1 [2.5–9.4]
  6.8 [3.7–11.6]
  1.7 [0.4–4.6]
  0.6 [0.0–2.8]
  0.6 [0.0–2.8]
  0.6 [0.0–2.8]
11.9 [7.6–17.9]
  1.1 [0.2–3.7]
  0.6 [0.0–2.8]
  1.1 [0.2–3.7]
  0.6 [0.0–2.8]
  0.6 [0.0–2.8]
  1.1 [0.2–3.7]
  1.1 [0.2–3.7]
  0.6 [0.0–2.8]
  0.6 [0.0–2.8]
  2.3 [0.7–5.5]
  0.6 [0.0–2.8]
  0.6 [0.0–2.8]
  0.6 [0.0–2.8]
  0.6 [0.0–2.8]
  1.1 [0.2–3.7]
  0.6 [0.0–2.8]
  0.6 [0.0–2.8]
Cardiovascular events
  Cerebrovascular accident (n patients)
  Cerebrovascular accident (n events)
  1
  1
  3
  0.6 [0.0–2.8]
  0.6 [0.0–2.8]
  1.7 [0.4–4.6]
Side-effects which were reason to discontinue secukinumab (n = 16)
  Recurrent mucosal fungal infections
  Fungal infection (oroph. and vaginal) and perleche
  Fungal infection (oroph.) and pharyngitis
  Generalised drug eruption
  General erythema (and rosacea and folliculitis)
  Worsening of bronchitis and micturition complaints 
  Headache and hypertension
  Injection site reactions, shortness of breath, fatigue
  Fatigue, dizziness, polyuria
  Dizziness and nausea
  Rhinitis and itching skin
  Erysipelas and upper respiratory tract infection
  Shortness of breath
  Increased gamma-glutamyl transferaseb
2
1
1
2
1
1
1
1
1
1
1
1
1
1
*Incidence rate (IR), expressed as number of events per 100 patient years. 
Incidence rates were calculated in 2 ways: (i) adverse events were counted only 
once per patient (recurrences not taken into account), and number of adverse 
events were divided by the total follow-up duration of our population (complete 
period of secukinumab exposure, measured in patient years), (ii) for recurrent 
events, also cumulative number of events (n events) was counted and divided by 
the total follow-up duration of the population (complete period of secukinumab 
exposure, measured in patient years). **Includes 4 patients with “chronic 
candidiasis”’, these patients were counted as having only one event. aCandidiasis 
was often not confirmed by laboratory tests (swab, culture). bDdx: medically 
induced hepatitis, hepatic steatosis.
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experienced at least one episode of fungal infection, and 
13 patients (7%) experienced at least one oropharyng-
eal fungal infection. The incidence rate (IR; first event 
per 100 patient years) was 14.2 (95% CI 9.4–20.6) for 
fungal infections in general, and 7.4 (95% CI 4.1–12.3) 
for oropharyngeal fungal infections. IRs based on cumu-
lative number of events (in case events occurred more 
than once per patient) are shown in Table III. 
Drug survival 
The 12 and 18 months overall drug survival of secukinu-
mab was 76% and 67%, respectively (Fig. 1a). The 12 
and 18 months drug survival related to ineffectiveness 
was 80% and 72% (Fig. 1b); the 12 and 18 months drug 
survival related to side-effects was 91% and 90% (Fig. 
1c). Median survival time could not be determined, be-
cause the Kaplan–Meier survival curve remains above 
50% for the whole observation period. Mean drug sur-
vival time was 15.0 months (95% CI 14.2–15.8). Mean 
drug survival may lack clinical relevance, however, as 
it is dependent on the follow-up duration.
Fig. 2 shows drug survival rates for separate groups 
based on treatment history. Fig. 2a shows biologic naive 
vs. experienced patients; however, this graph should be 
interpreted with care due to the small number of naive 
patients (33 patients; 17%). Split for patients with ≤ 1 
(naive or “near naive”) vs. > 1 prior biologic (Fig. 2b), 
the 18 months overall drug survival was 82% and 62%, 
respectively (no log-rank test performed due to crossing 
of curves). Drug survival related to ineffectiveness after 
18 months was 90% for patients with ≤ 1 prior biologics, 
vs. 65% for patients with > 1 prior biologic (p = 0.021; 
Fig. 1. Drug survival of secukinumab, split for reason of discontinuation. (a–c) “n” at risk was 196 at baseline, 146 at 6 months, 83 at 12 months, 
and 33 at 18 months.
Fig. 2. Overall drug survival of 
secukinumab, split for prior biologic 
use. (a) “n” at risk for naive patients: 
33 at baseline, 25 at 6 months, 11 at 12 
months, and 3 at 18 months. “n” at risk 
for experienced patients: 163 at baseline, 
121 at 6 months, 72 at 12 months, and 
30 at 18 months. (b) “n” at risk for naive 
or near-naive patients: 71 at baseline, 
53 at 6 months, 26 at 12 months, and 7 
at 18 months. “n” at risk for experienced 
patients: 125 at baseline, 93 at 6 months, 
57 at 12 months, and 26 at 18 months. §No 
log-rank test performed due to crossing 
of curves. 
1https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-2900
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see Fig. S2b1). The side-effects-related drug survival at 
18 months was comparable for the two groups (90% and 
89%, respectively). 
Split according to sex, the overall drug survival was 
78% for men vs. 73% for women after 12 months, and 
66% for men vs. 68% for women after 18 months (Fig. 
S3a1). Drug survival related to ineffectiveness after 12 
and 18 months was similar across sexes: 80% vs. 79% 
and 70% vs. 74% for men vs. women, respectively. In 
contrast, side-effects related drug survival emphasized 
sex differences, with 12-month survival 95% for men vs. 
84% for women, and 18-month survival of 93% in men 
vs. 84% in women (Fig. S3c1). Drug survival did not 
differ when comparing retrospectively vs. prospectively 
collected data (Fig. S31).
Univariate Cox regression analysis of determinants of 
drug survival is shown in Table SI1. Univariate analysis 
showed that higher age, higher baseline weight and prior 
use of >1 biologic could be associated with decreased 
secukinumab drug survival (p < 0.05, or 95% CI > 1). 
Psoriatic arthritis was not associated with drug survival 
in univariate analyses. A multivariate Cox regression 
analysis would be needed to establish the strength of 
the independent associations of these variables, but such 
regression analyses were not performed because of the 
many (non-random) missing data for baseline variables.
DISCUSSION
This daily practice study, based on 196 patients receiving 
secukinumab for psoriasis, showed an overall drug survi-
val rate of 76% after 12 and 67% after 18 months. Drug 
survival was predominantly determined by discontinua-
tion due to ineffectiveness (64% of all discontinuations). 
A smaller part (15%) of discontinuations was related to 
side-effects, concerning mostly fungal infections of the 
oropharyngeal mucosa. Sixteen percent of discontinua-
tions were due to a combination of ineffectiveness and 
side-effects. The majority (66%) of patients who discon-
tinued secukinumab due to ineffectiveness, comprised 
cases who showed a good initial response, but later 
experienced loss of effect. Another group recently pu-
blished a case series describing secondary ineffectiveness 
in 19% of patients, occurring mostly after 24–32 weeks 
of treatment (12). Drug survival curves in our study did 
not suggest a sudden loss of secukinumab efficacy after 
6 months of treatment. Rather, discontinuations occur-
red spread over the entire follow-up period, leading to 
a gradual decrease in drug survival over time (Fig. 1).
Comparing the current results with existing literature, 
drug survival rates of secukinumab were in the range of 
those reported for anti-TNF agents. The 12-month drug 
survival of adalimumab and etanercept, as reported in 
literature, ranged from 75% to 84% and from 70% to 
86%, respectively (10, 13–16). Ustekinumab showed 
superior drug survival in previous drug survival studies, 
with 12-month drug survival rates ranging from 84% 
to 95% (10, 13–16). In addition, drug survival rates 
from Dutch psoriasis patients (adalimumab, etaner-
cept, ustekinumab, infliximab; BioCAPTURE registry) 
are visualized and added as a supplemental file, and 
positioned next to secukinumab drug survival (Fig. 
S11). It is surprising to find higher drug survival rates 
for ustekinumab compared with secukinumab in both 
literature and our own data, given that secukinumab 
showed superior efficacy to ustekinumab in a head-to-
head trial (CLEAR study) (6). A recent drug survival 
analysis of Egeberg et al. showed slightly lower drug 
survival rates for secukinumab (estimated 1-year drug 
survival 68%) (17). The authors used a 60-day threshold 
as a maximum gap to determine discontinuation, where 
in the present analysis and other drug survival studies 
90 days was used (9, 10, 13, 14, 18–21). In our present 
study, drug survival was compared using 90 and 60 days 
thresholds, which were virtually similar (Fig. S51). Al-
though not directly translatable to drug survival, Huang 
et al. (12) also showed a substantial proportion (30%) 
of patients stopping secukinumab within 32 weeks. 
However, comparisons between drug survival rates of 
other biologics and secukinumab data are hindered by 
patient population differences. For instance, our cohort 
comprises patients who started secukinumab treatment 
soon after it became available. New agents are generally 
introduced more promptly in patients who have failed on 
(all) other treatments. As a consequence, difficult-to-treat 
patients were possibly over-represented in the present 
study. This may be reflected by the small proportion of 
biologic-naive patients in our cohort (17%), compared 
with cohorts from previous drug survival studies. For 
biologic experienced patients, reason of prior treatment 
discontinuation was often unknown. However, previous 
studies on drug survival of biologics in psoriasis have 
shown that the majority of patients discontinue due to 
ineffectiveness, and only a minority due to side-effects.
To explore whether naivety for biologics was a factor 
influencing drug survival rates for secukinumab, we 
performed subanalyses for naive patients, patients with 
≤ 1 prior biologics (naive or “near naive”) and patients 
who had received multiple prior biologics. A striking 
difference in 18 months drug survival rates was found 
between patients with ≤ 1 biologics and patients with 
> 1 prior biologic (82% vs. 62%, respectively). The 
difference between naive and experienced patients fol-
lowed the same pattern, but sample size of truly naive 
patients was limited (33 patients). The difference in drug 
survival curves between patients with ≤ 1 and patients 
with > 1 biologic was mainly determined by a higher 
number of discontinuations due to ineffectiveness in 
the (near) naive biologic group. Discontinuation due to 
side-effects did not differ between the ≤ 1 and > 1 prior 
biologic group (Fig. S21). Previous biologic use was not 
an exclusion criterion for secukinumab trials, but the trial 
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population was dominated by naive patients nonetheless, 
with 71–88% of patients being biologic-naive (3). This 
differs clearly from the composition of the present study 
cohort. Comparing other characteristics of trial patients 
with our cohort, we found that the present study included 
more female patients (39%, vs. 23–36% in trials) and 
that patients were slightly older (mean 48.9 years vs. 
43.9–46.6 years in trials) (3–6). Mean baseline PASI in 
our cohort was 13.4 (median 10.9), but there were many 
missing values. In comparison, the mean baseline PASI 
ranged from 18.9 to 23.9 in the secukinumab trials (3–6). 
Our findings demonstrate that, due to specific differences 
in population characteristics, daily practice results may 
diverge from trial findings, stressing the importance of 
the former when assessing an agents’ effectiveness.
In drug survival analyses performed for other biolo-
gics, sex differences were often noticed. Women fre-
quently showed lower biologic drug survival rates than 
men (10, 13, 14, 22). A specific relation to side-effects 
(women stopping a drug due to side-effects more often 
than men) was previously observed in our BioCAPTURE 
cohort (13). In the present study, there was a trend 
towards shorter secukinumab drug survival for women 
after 12 months, but not after 18 months. A trend for 
shorter drug survival related to side-effects was detected 
in women compared with men. 
Fungal infections were common in our population, 
with 13% of patients experiencing at least one episode 
of a fungal infection during treatment. The incidence 
rates per 100 patient years for fungal infections were 
14.2 (counting only the first event per patient) and 21.6 
(counting all events), which is higher than incidence rates 
of Candida infections found in trials (IR 3.6 in patients 
on 300 mg every 4 weeks; IR 1.9 in patients on 150 mg 
every 4 weeks) (23). Notably, adverse events could be 
under-reported in our cohort, given that part of the data 
was retrospectively collected. The mucosa was predomi-
nantly affected in the current study, with 7% of patients 
experiencing at least one episode of oropharyngeal fungal 
infection. Four patients in the current cohort ultimately 
stopped secukinumab treatment due to (recurrent) fungal 
infections, in contrast to the secukinumab trials where 
treatment discontinuations due to fungal infections did 
not occur (3–6, 24).
The main limitation of the current study is that part 
of the data was retrospectively collected. This probably 
did not influence drug survival itself as variables related 
to such analyses (medication start and stop dates) are 
normally properly registered in daily practice. Cor-
respondingly, we did not find differences in drug survival 
curves when splitting for method of data collection (Fig. 
S41). Reporting of adverse events, however, may differ 
in retrospective cases when compared with prospectively 
followed patients. Subanalyses of adverse events showed 
that fungal infections were reported more frequently in 
prospectively followed patients than in retrospective 
cases, although the number of oropharyngeal fungal 
infections did not differ (data not shown). Another li-
mitation is the small number of biologic naive patients, 
hampering the analysis of naive vs. experienced patients. 
In summary, there was a 76% overall drug survival of 
secukinumab after 12 months, which is comparable to 
drug survival of adalimumab and etanercept, and inferior 
to drug survival of ustekinumab as described in literature. 
However, direct comparisons are not possible due to the 
observational nature of data, and differences in patient 
characteristics (amongst others, included secukinumab 
patients often failed multiple prior biologics). Patients 
stopped mostly due to ineffectiveness and less frequently 
due to side-effects. A trend towards shorter drug survival 
related to side-effects was detected in women compared 
with men. It is important to realise that the reported 
drug survival represents secukinumab performance in 
an initial cohort of secukinumab-treated patients, where 
patients with difficult-to-treat psoriasis are possibly over-
represented. Indeed, drug survival rates of patients who 
had used ≤ 1 prior biologic were higher when compared 
with patients who had used multiple prior biologics. 
Furthermore, we found that oropharyngeal fungal infec-
tions were more common than expected based on trial 
data, and were reason for treatment discontinuation in 
some cases. Our findings illustrate the importance of 
daily practice studies in complementing data from ran-
domized controlled trials.
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